One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...